IslamabadPakistan’s supply of one insulin product fell from 3,500 kits to 1,000.

Alternatives cost at least 20% more, lawmaker Amna Batool told the National Assembly.

Health parliamentary secretary Nelson Azeem said the German maker halted production for a year-long upgrade.

The health ministry says only 1 brand, Sanofi’s Apidra, is unavailable and rival rapid-acting insulins are stocked nationwide.

The product returns only when German supply is restored, Azeem said, and supplies could fall further first.

How each outlet framed it
Dawn leans critical
reports the parliamentary exchange where alternatives cost at least 20% more and many patients lack access to doctors

Sources: Dawn